[
    [
        {
            "time": "2018-03-15",
            "original_text": "Top Analyst Reports for Novo Nordisk, NextEra & 3M Company",
            "features": {
                "keywords": [
                    "analyst reports",
                    "Novo Nordisk",
                    "NextEra",
                    "3M"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "industrial"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Analyst Reports for Novo Nordisk, NextEra & 3M Company",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Gilead, Novo Nordisk Expand NASH Collaboration",
            "features": {
                "keywords": [
                    "Gilead",
                    "Novo Nordisk",
                    "NASH",
                    "collaboration"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Gilead, Novo Nordisk Expand NASH Collaboration",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study",
            "features": {
                "keywords": [
                    "Gilead",
                    "Novo Nordisk",
                    "triple combo therapy",
                    "NASH",
                    "study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Gilead and Novo Nordisk Expand NASH Clinical Collaboration",
            "features": {
                "keywords": [
                    "Gilead",
                    "Novo Nordisk",
                    "NASH",
                    "clinical collaboration"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Gilead and Novo Nordisk Expand NASH Clinical Collaboration",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]